ArticleEye (London, England)2026
Large-scale analysis of risk factors for developing retinal vein occlusion in the fellow eye.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe main objective was to elucidate the associations for developing a fellow-eye retinal vein occlusion (RVO) after a patient experiences a first-time unilateral RVO event. SUBJECTS/
methodsLarge, multicenter, retrospective study using the global TriNetX database. We included patients newly diagnosed with unilateral RVO from 1 January 2015 to 1 January 2025. We estimated the incidence of fellow-eye RVO using Kaplan-Meier survival analysis, compared baseline demographic and medical characteristics between groups with and without progression to bilateral RVO and calculated hazard ratios with 95% confidence intervals for fellow-eye RVO based on various systemic and ocular comorbidities.
results437 of 22,969 patients (1.90%) developed RVO in the fellow eye. Patients with fellow-eye RVO had higher rates of primary open-angle glaucoma (POAG; 22% vs. 17%, p = 0.006), dry age-related macular degeneration (AMD; 15% vs. 12%, p = 0.008) and anemia (39% vs. 31%, p = 0.0001). They also were more likely to self-identify as Black/African American (21% vs. 17%, p = 0.03) and less likely to be White (50% vs. 58%, p = 0.0008). No significant difference was identified between mean age, sex, or rates of traditional cardiovascular risk factors across these two groups. There was a 1.41- (95% CI 1.03-1.94), 1.46- (95% CI 1.02-2.10) and 1.84-fold (95% CI 1.38-2.47) increased hazard of developing bilateral sequential RVO with baseline POAG, dry AMD and anemia, respectively.
conclusionThe presence of primary open-angle glaucoma, dry age-related macular degeneration and anemia is significantly associated with fellow-eye RVO and may help prognosticate the development of progressive disease in patients with unilateral RVO.
Identifiers
42547533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.